Przejdź do zawartości
Merck

I0150000

Indapamide

European Pharmacopoeia (EP) Reference Standard

Synonim(y):

N-(4-Chloro-3-sulfamoylbenzamido)-2-methylindoline

Zaloguj sięWyświetlanie cen organizacyjnych i kontraktowych


About This Item

Wzór empiryczny (zapis Hilla):
C16H16ClN3O3S
Numer CAS:
Masa cząsteczkowa:
365.83
Numer MDL:
Kod UNSPSC:
41116107
Identyfikator substancji w PubChem:
NACRES:
NA.24

klasa czystości

pharmaceutical primary standard

rodzina API

indapamide

producent / nazwa handlowa

EDQM

Zastosowanie

pharmaceutical (small molecule)

format

neat

temp. przechowywania

2-8°C

ciąg SMILES

CC1Cc2ccccc2N1NC(=O)c3ccc(Cl)c(c3)S(N)(=O)=O

InChI

1S/C16H16ClN3O3S/c1-10-8-11-4-2-3-5-14(11)20(10)19-16(21)12-6-7-13(17)15(9-12)24(18,22)23/h2-7,9-10H,8H2,1H3,(H,19,21)(H2,18,22,23)

Klucz InChI

NDDAHWYSQHTHNT-UHFFFAOYSA-N

informacje o genach

human ... SLC12A3(6559)

Szukasz podobnych produktów? Odwiedź Przewodnik dotyczący porównywania produktów

Opis ogólny

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Zastosowanie

Indapamide EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Opakowanie

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Inne uwagi

Sales restrictions may apply.
This page may contain text that has been machine translated.

Piktogramy

Health hazard

Hasło ostrzegawcze

Warning

Zwroty wskazujące rodzaj zagrożenia

Zwroty wskazujące środki ostrożności

Klasyfikacja zagrożeń

Lact. - Repr. 2

Kod klasy składowania

11 - Combustible Solids

Klasa zagrożenia wodnego (WGK)

WGK 2

Temperatura zapłonu (°F)

Not applicable

Temperatura zapłonu (°C)

Not applicable


Choose from one of the most recent versions:

Certyfikaty analizy (CoA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Obsługa Klienta

Masz już ten produkt?

Dokumenty związane z niedawno zakupionymi produktami zostały zamieszczone w Bibliotece dokumentów.

Odwiedź Bibliotekę dokumentów

J J Mourad et al.
Current medical research and opinion, 25(9), 2271-2280 (2009-07-25)
Despite the widespread notion that controlling hypertension is essential to improve cardiovascular outcome, uncontrolled hypertension rates remain high. Fixed-dose combinations are used routinely to reduce the impact of hypertension. Treatment with fixed-combination perindopril/indapamide, for example, at the currently approved doses
P W de Leeuw
Journal of hypertension. Supplement : official journal of the International Society of Hypertension, 19(3), S41-S45 (2001-11-21)
Most patients with hypertension will need, at some stage, more than one drug to lower their blood pressure. Although monotherapy is still the preferred option for first-line treatment of hypertension, low-dose combination therapy as the initial medication has been increasingly
R Donnelly
Clinical pharmacokinetics, 37 Suppl 1, 21-32 (1999-09-24)
Recent international guidelines on the detection, clinical assessment and management of patients with hypertension have highlighted a number of themes that should be incorporated into routine clinical practice. First, although antihypertensive therapy is having a major impact on reducing the
Peter W de Leeuw
Expert opinion on pharmacotherapy, 12(11), 1827-1833 (2011-06-10)
Hypertension is an important risk factor for cardiovascular complications and the need to treat this condition has been well established. Despite the availability of many antihypertensive drugs, it is often necessary to combine several of these drugs. The compound perindopril/indapamide
Stéphane Laurent
Journal of hypertension. Supplement : official journal of the International Society of Hypertension, 21(3), S11-S18 (2003-08-22)
To review the safety and efficacy of the very-low-dose combination of perindopril 2 mg and indapamide 0.625 mg (Per2/Ind0.625) in essential hypertension, in relation to blood pressure control and target-organ damage. We included in this review several double-blind, randomized studies

Nasz zespół naukowców ma doświadczenie we wszystkich obszarach badań, w tym w naukach przyrodniczych, materiałoznawstwie, syntezie chemicznej, chromatografii, analityce i wielu innych dziedzinach.

Skontaktuj się z zespołem ds. pomocy technicznej